KCTD5 and chronic myelogenous leukemia, BCR-ABL1 positive: Following Adnan Awad and colleagues’ study, further mechanistic studies are required to prove how KCTD5 mediates TKI resistance, how TKI-resistant CML patients downregulate KCTD5, and whether this can be exploited therapeutically.